JP2009542819A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009542819A5 JP2009542819A5 JP2009530697A JP2009530697A JP2009542819A5 JP 2009542819 A5 JP2009542819 A5 JP 2009542819A5 JP 2009530697 A JP2009530697 A JP 2009530697A JP 2009530697 A JP2009530697 A JP 2009530697A JP 2009542819 A5 JP2009542819 A5 JP 2009542819A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- ssri
- snri
- composition
- telenzepine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000935 antidepressant agent Substances 0.000 claims description 13
- 229940005513 antidepressants Drugs 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- VSWPGAIWKHPTKX-UHFFFAOYSA-N 1-methyl-10-[2-(4-methyl-1-piperazinyl)-1-oxoethyl]-5H-thieno[3,4-b][1,5]benzodiazepin-4-one Chemical compound C1CN(C)CCN1CC(=O)N1C2=CC=CC=C2NC(=O)C2=CSC(C)=C21 VSWPGAIWKHPTKX-UHFFFAOYSA-N 0.000 claims description 11
- 229950004351 telenzepine Drugs 0.000 claims description 11
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims description 7
- 229960002464 fluoxetine Drugs 0.000 claims description 7
- 229960002073 sertraline Drugs 0.000 claims description 7
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims description 7
- 229960004688 venlafaxine Drugs 0.000 claims description 7
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims description 7
- 230000001430 anti-depressive effect Effects 0.000 claims description 6
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims description 2
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 2
- 238000013268 sustained release Methods 0.000 claims 2
- 239000012730 sustained-release form Substances 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229940076279 serotonin Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 description 22
- 239000005557 antagonist Substances 0.000 description 17
- 229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 description 6
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 6
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 6
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 description 6
- 208000019022 Mood disease Diseases 0.000 description 4
- 230000003340 mental effect Effects 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 208000017194 Affective disease Diseases 0.000 description 2
- 229940094659 Dopamine reuptake inhibitor Drugs 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000221 dopamine uptake inhibitor Substances 0.000 description 2
- 230000006996 mental state Effects 0.000 description 2
- RMHMFHUVIITRHF-UHFFFAOYSA-N pirenzepine Chemical compound C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 RMHMFHUVIITRHF-UHFFFAOYSA-N 0.000 description 2
- 229960004633 pirenzepine Drugs 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 description 1
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- KYYIDSXMWOZKMP-UHFFFAOYSA-N O-desmethylvenlafaxine Chemical compound C1CCCCC1(O)C(CN(C)C)C1=CC=C(O)C=C1 KYYIDSXMWOZKMP-UHFFFAOYSA-N 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- 229940111055 Serotonin-norepinephrine-dopamine reuptake inhibitor Drugs 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960001653 citalopram Drugs 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 229960001623 desvenlafaxine Drugs 0.000 description 1
- 229960002866 duloxetine Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229960004341 escitalopram Drugs 0.000 description 1
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 1
- 229960004038 fluvoxamine Drugs 0.000 description 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960000600 milnacipran Drugs 0.000 description 1
- 229960001785 mirtazapine Drugs 0.000 description 1
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 230000003551 muscarinic effect Effects 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000952 serotonin receptor agonist Substances 0.000 description 1
- 230000000697 serotonin reuptake Effects 0.000 description 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 239000003174 triple reuptake inhibitor Substances 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80506606P | 2006-06-16 | 2006-06-16 | |
| US60/805,066 | 2006-06-16 | ||
| US82922506P | 2006-10-12 | 2006-10-12 | |
| US60/829,225 | 2006-10-12 | ||
| US11/763,145 US7893053B2 (en) | 2006-06-16 | 2007-06-14 | Treating psychological conditions using muscarinic receptor M1 antagonists |
| US11/763,145 | 2007-06-14 | ||
| PCT/US2007/071356 WO2007147123A1 (en) | 2006-06-16 | 2007-06-15 | Treating psychological conditions using muscarinic receptor m1 antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011224234A Division JP5491475B2 (ja) | 2006-06-16 | 2011-10-11 | ムスカリン性受容体ｍ１拮抗剤を使用する精神状態の処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009542819A JP2009542819A (ja) | 2009-12-03 |
| JP2009542819A5 true JP2009542819A5 (enExample) | 2011-12-01 |
| JP4874397B2 JP4874397B2 (ja) | 2012-02-15 |
Family
ID=38832129
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009530697A Expired - Fee Related JP4874397B2 (ja) | 2006-06-16 | 2007-06-15 | ムスカリン性受容体ｍ１拮抗剤を使用する精神状態の処置 |
| JP2011224234A Expired - Fee Related JP5491475B2 (ja) | 2006-06-16 | 2011-10-11 | ムスカリン性受容体ｍ１拮抗剤を使用する精神状態の処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011224234A Expired - Fee Related JP5491475B2 (ja) | 2006-06-16 | 2011-10-11 | ムスカリン性受容体ｍ１拮抗剤を使用する精神状態の処置 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US7893053B2 (enExample) |
| EP (2) | EP2032127B1 (enExample) |
| JP (2) | JP4874397B2 (enExample) |
| KR (1) | KR101408650B1 (enExample) |
| CN (1) | CN103041389A (enExample) |
| AU (1) | AU2007260631B2 (enExample) |
| BR (1) | BRPI0713733A2 (enExample) |
| CA (1) | CA2655131C (enExample) |
| IL (1) | IL195857A (enExample) |
| MX (1) | MX2008015887A (enExample) |
| NZ (1) | NZ573570A (enExample) |
| RU (1) | RU2012152922A (enExample) |
| SG (1) | SG172712A1 (enExample) |
| WO (1) | WO2007147123A1 (enExample) |
| ZA (2) | ZA200810680B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7893053B2 (en) * | 2006-06-16 | 2011-02-22 | Theracos, Inc. | Treating psychological conditions using muscarinic receptor M1 antagonists |
| US8748419B2 (en) | 2006-06-16 | 2014-06-10 | Theracos, Inc. | Treating obesity with muscarinic receptor M1 antagonists |
| WO2010006249A1 (en) * | 2008-07-10 | 2010-01-14 | Tyrx Pharma, Inc. | Sustained release formulations of psychoactive drugs |
| WO2010028130A2 (en) * | 2008-09-03 | 2010-03-11 | Concert Pharmaceuticals, Inc. | Antidepressant compounds |
| US20110021507A1 (en) * | 2009-07-22 | 2011-01-27 | Theracos, Inc. | Inhibiting antipsychotic-induced weight gain |
| EP2510949A4 (en) * | 2009-12-11 | 2013-11-13 | Astellas Pharma Inc | THERAPEUTICS FOR FIBROMYALGIA |
| PL2632468T3 (pl) * | 2010-10-25 | 2018-04-30 | University Of Manitoba | Kompozycje terapeutyczne do leczenia symetrycznej polineuropatii cukrzycowej |
| WO2020206410A1 (en) * | 2019-04-04 | 2020-10-08 | University Of Maryland, Baltimore | Methods of using muscarinic antagonists in the treatment of depression |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1795183B1 (de) | 1968-08-20 | 1972-07-20 | Thomae Gmbh Dr K | 5,11-Dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-on-derivate und Arzneimittel |
| US4172831A (en) | 1974-11-26 | 1979-10-30 | Lilly Industries Limited | Thieno-benzodiazepines |
| US3953430A (en) | 1975-02-24 | 1976-04-27 | American Cyanamid Company | Substituted benzodiazepin-10-ones and method of use |
| US4168269A (en) | 1978-04-12 | 1979-09-18 | American Cyanamid Company | Substituted thieno-benzodiazepines |
| US4536518A (en) | 1979-11-01 | 1985-08-20 | Pfizer Inc. | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine |
| US4381301A (en) | 1980-05-07 | 1983-04-26 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Substituted tricyclic thieno compounds, their synthesis, their use, their compositions and their medicaments |
| US4933438A (en) | 1984-02-29 | 1990-06-12 | University Of Florida | Brain-specific analogues of centrally acting amines |
| US6150354A (en) | 1987-01-15 | 2000-11-21 | Bonnie Davis | Compounds for the treatment of Alzheimer's disease |
| US4839104A (en) | 1987-06-11 | 1989-06-13 | Pfizer, Inc. | Process for preparing sertraline intermediates |
| US4904731A (en) * | 1987-09-04 | 1990-02-27 | Shell Oil Company | Polymeric composition |
| US4952128A (en) * | 1987-09-22 | 1990-08-28 | Chicopee | Transverse web forming apparatus |
| EP0386145A1 (de) | 1987-12-22 | 1990-09-12 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Thienotricyclen zur behandlung von erkrankungen der bronchien |
| US5114976A (en) | 1989-01-06 | 1992-05-19 | Norden Michael J | Method for treating certain psychiatric disorders and certain psychiatric symptoms |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| US4940731A (en) | 1989-08-30 | 1990-07-10 | Pfizer Inc. | Method of treating premature ejaculation using sertraline |
| US5130338A (en) | 1989-08-30 | 1992-07-14 | Pfizer Inc. | Method of treating chemical dependencies using sertraline |
| US4962128A (en) | 1989-11-02 | 1990-10-09 | Pfizer Inc. | Method of treating anxiety-related disorders using sertraline |
| WO1992020327A1 (en) | 1991-05-14 | 1992-11-26 | Ernir Snorrason | Treatment of fatigue syndrome with cholinesterase inhibitors |
| IT1250421B (it) | 1991-05-30 | 1995-04-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato con proprieta' bio-adesive. |
| US5324832A (en) | 1991-07-03 | 1994-06-28 | The United States Of America As Represented By The Department Of Health And Human Services | Muscarinic antagonists |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| US5248699A (en) | 1992-08-13 | 1993-09-28 | Pfizer Inc. | Sertraline polymorph |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| FR2710265B1 (fr) | 1993-09-22 | 1995-10-20 | Adir | Composition pharmaceutique bioadhésive pour la libération contrôlée de principes actifs. |
| US5597826A (en) | 1994-09-14 | 1997-01-28 | Pfizer Inc. | Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist |
| US6548084B2 (en) | 1995-07-20 | 2003-04-15 | Smithkline Beecham Plc | Controlled release compositions |
| US6245347B1 (en) | 1995-07-28 | 2001-06-12 | Zars, Inc. | Methods and apparatus for improved administration of pharmaceutically active compounds |
| DE19541260A1 (de) | 1995-11-06 | 1997-05-07 | Lohmann Therapie Syst Lts | Therapeutische Zubereitung zur transdermalen Applikation von Wirkstoffen durch die Haut |
| US6512010B1 (en) | 1996-07-15 | 2003-01-28 | Alza Corporation | Formulations for the administration of fluoxetine |
| HU222341B1 (hu) * | 1996-12-18 | 2003-06-28 | Richter Gedeon Vegyészeti Gyár Rt. | Eljárás sertralin előállítására és az eljárásban alkalmazott intermedier |
| DE69725113T2 (de) | 1997-02-25 | 2004-07-15 | Akzo Nobel N.V. | Azetidin- und Pyrrolidinderivate |
| SK180499A3 (en) | 1997-07-01 | 2001-08-06 | Pfizer | Sertraline salts and sustained-release dosage forms of sertraline |
| CA2301883A1 (en) | 1997-09-11 | 1999-03-18 | Nycomed Danmark A/S | Modified release multiple-units compositions of non-steroid anti-inflammatory drug substances (nsaids) |
| US6624200B2 (en) | 1998-08-25 | 2003-09-23 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets |
| SE9703375D0 (sv) | 1997-09-18 | 1997-09-18 | Astra Ab | A new combination |
| US6607751B1 (en) | 1997-10-10 | 2003-08-19 | Intellipharamaceutics Corp. | Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum |
| US6403597B1 (en) | 1997-10-28 | 2002-06-11 | Vivus, Inc. | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation |
| US6248864B1 (en) | 1997-12-31 | 2001-06-19 | Adherex Technologies, Inc. | Compounds and methods and modulating tissue permeability |
| US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
| US6312717B1 (en) | 1998-07-07 | 2001-11-06 | Bristol-Myers Squibb Company | Method for treatment of anxiety and depression |
| US6331571B1 (en) | 1998-08-24 | 2001-12-18 | Sepracor, Inc. | Methods of treating and preventing attention deficit disorders |
| US20020009478A1 (en) | 1998-08-24 | 2002-01-24 | Douglas Joseph Dobrozsi | Oral liquid mucoadhesive compositions |
| SE9802864D0 (sv) | 1998-08-27 | 1998-08-27 | Pharmacia & Upjohn Ab | Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder |
| IL141762A0 (en) | 1998-10-01 | 2002-03-10 | Novartis Ag | New oral formulations |
| US6727283B2 (en) | 1998-10-13 | 2004-04-27 | Pfizer Inc. | Sertraline oral concentrate |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| FR2792527B1 (fr) | 1999-04-22 | 2004-08-13 | Ethypharm Lab Prod Ethiques | Microgranules de ketoprofene, procede de preparation et compositions pharmaceutiques |
| US6541020B1 (en) | 1999-07-09 | 2003-04-01 | Trimeris, Inc. | Methods and compositions for administration of therapeutic reagents |
| US6562375B1 (en) | 1999-08-04 | 2003-05-13 | Yamanouchi Pharmaceuticals, Co., Ltd. | Stable pharmaceutical composition for oral use |
| EP1207860B1 (en) | 1999-09-02 | 2007-10-24 | Nostrum Pharmaceuticals, Inc. | Controlled release pellet formulation |
| US6544548B1 (en) | 1999-09-13 | 2003-04-08 | Keraplast Technologies, Ltd. | Keratin-based powders and hydrogel for pharmaceutical applications |
| US6080736A (en) | 1999-10-27 | 2000-06-27 | Janus Pharmaceuticals, Inc. | Methods and compositions for treating and preventing anxiety and anxiety disorders using optically pure (R) tofisopam |
| US6461631B1 (en) | 1999-11-16 | 2002-10-08 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
| AU2463701A (en) | 1999-12-29 | 2001-07-09 | Nanodelivery, Inc. | Drug delivery system exhibiting permeability control |
| US6589549B2 (en) | 2000-04-27 | 2003-07-08 | Macromed, Incorporated | Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles |
| US6524621B2 (en) | 2000-05-01 | 2003-02-25 | Aeropharm Technology Inc. | Core formulation |
| US6482440B2 (en) | 2000-09-21 | 2002-11-19 | Phase 2 Discovery, Inc. | Long acting antidepressant microparticles |
| US6524615B2 (en) | 2001-02-21 | 2003-02-25 | Kos Pharmaceuticals, Incorporated | Controlled release pharmaceutical composition |
| WO2002072145A1 (en) | 2001-03-14 | 2002-09-19 | Ono Pharmaceutical Co., Ltd. | Remedies for depression containing ep1 antagonist as the active ingredient |
| US20050226920A1 (en) | 2004-04-13 | 2005-10-13 | Kirk Voelker | Method of decreasing nicotine withdrawal symptoms during smoking cessation. |
| JP2008509147A (ja) | 2004-08-05 | 2008-03-27 | アカディア ファーマシューティカルズ，インコーポレーテッド | ヒト神経精神病を治療するためのｎ−デスメチルクロザピンの使用 |
| JP2008537961A (ja) | 2005-04-15 | 2008-10-02 | ボード、オブ、トラスティーズ、オブ、ミシガン、ステイト、ユニバーシティ | Ｇｐｃｒモジュレーター |
| US8859585B2 (en) | 2005-05-25 | 2014-10-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Scopolamine for the treatment of depression and anxiety |
| WO2007105120A1 (en) | 2006-03-14 | 2007-09-20 | Nxp B.V. | Automatically configurable smart card and method of automatically configuring a smart card |
| US7893053B2 (en) | 2006-06-16 | 2011-02-22 | Theracos, Inc. | Treating psychological conditions using muscarinic receptor M1 antagonists |
| UA98938C2 (ru) | 2006-06-16 | 2012-07-10 | Теракос, Инк. | Лечение психологических состояний с применением антагонистов мускариновых рецепторов м1 |
-
2007
- 2007-06-14 US US11/763,145 patent/US7893053B2/en not_active Expired - Fee Related
- 2007-06-15 JP JP2009530697A patent/JP4874397B2/ja not_active Expired - Fee Related
- 2007-06-15 NZ NZ573570A patent/NZ573570A/en not_active IP Right Cessation
- 2007-06-15 BR BRPI0713733-8A patent/BRPI0713733A2/pt not_active IP Right Cessation
- 2007-06-15 EP EP07784456.1A patent/EP2032127B1/en not_active Not-in-force
- 2007-06-15 KR KR1020097000753A patent/KR101408650B1/ko not_active Expired - Fee Related
- 2007-06-15 CN CN2012103367136A patent/CN103041389A/zh active Pending
- 2007-06-15 SG SG2011043882A patent/SG172712A1/en unknown
- 2007-06-15 MX MX2008015887A patent/MX2008015887A/es active IP Right Grant
- 2007-06-15 AU AU2007260631A patent/AU2007260631B2/en not_active Ceased
- 2007-06-15 CA CA2655131A patent/CA2655131C/en not_active Expired - Fee Related
- 2007-06-15 WO PCT/US2007/071356 patent/WO2007147123A1/en not_active Ceased
- 2007-06-15 EP EP12194224.7A patent/EP2666358A1/en not_active Withdrawn
-
2008
- 2008-12-11 IL IL195857A patent/IL195857A/en active IP Right Grant
- 2008-12-18 ZA ZA2008/10680A patent/ZA200810680B/en unknown
-
2010
- 2010-11-29 ZA ZA2010/08538A patent/ZA201008538B/en unknown
-
2011
- 2011-01-11 US US13/004,837 patent/US8735389B2/en not_active Expired - Fee Related
- 2011-10-11 JP JP2011224234A patent/JP5491475B2/ja not_active Expired - Fee Related
-
2012
- 2012-12-07 RU RU2012152922/15A patent/RU2012152922A/ru not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009542819A5 (enExample) | ||
| JP2012036212A5 (enExample) | ||
| JP2013544850A5 (enExample) | ||
| RU2019143572A (ru) | Композиции для лечения посттравматического стрессового расстройства | |
| RU2012152922A (ru) | Лечение психологических состояний с применением антагонистов м1-мускариновых рецепторов | |
| JP2023100904A5 (enExample) | ||
| RU2007103313A (ru) | Комбинация бупропина и другого состава для эффективной потери веса | |
| JP2016506933A5 (enExample) | ||
| JP2010534676A5 (enExample) | ||
| JP2009538331A (ja) | 抑うつ障害のための治療 | |
| JP2017141277A (ja) | 痛み治療用の医薬配合物 | |
| RU2011137131A (ru) | Производные 1-аминоалкилциклогексана для лечения тиннитуса, связанного с потерей слуха или незначительной потерей слуха | |
| JP2005523334A5 (enExample) | ||
| JP2009542820A5 (enExample) | ||
| Rogóz et al. | Mechanism of synergistic action following co-treatment with pramipexole and fluoxetine or sertraline in the forced swimming test in rats | |
| RU2020125170A (ru) | Композиции и способы улучшения биодоступности 5-гидрокситриптофана | |
| Reeves et al. | ICase Report | |
| Rubio et al. | Reboxetine adjunct for partial or nonresponders to antidepressant treatment | |
| JP2007513052A5 (enExample) | ||
| CO6260011A2 (es) | Uso de (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)-amida del acido 4-hidroxi-4-metil-piperidin-1- carboxilico para el tratamiento del trastorno por estres postraumatico | |
| JP2013032308A5 (enExample) | ||
| RU2009101143A (ru) | Лечение психологических состояний с применением антаггонистов m1-мускариновых рецепторов | |
| WO2008037045A3 (en) | Composition containing a mixture of antidepressants for treating premature ejaculation. | |
| JP2007513896A5 (enExample) | ||
| ES2332176T3 (es) | Formulacion antidepresiva oral que contiene un acido acetilsalicilico para acelerar su accion. |